|
| 33011099 | Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. | J Cyst Fibros | 2021 |
| 33675790 | Myeloid Dendritic Cells Are Major Producers of IFN-β in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness. | J Invest Dermatol | 2021 |
| 34323681 | A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. | Clin Exp Rheumatol | 2021 |
| 33164325 | Reply. | Arthritis Rheumatol | 2021 |
| 32336038 | Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. | Arthritis Rheumatol | 2020 |
| 27267753 | Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. | Arthritis Res Ther | 2016 |
| 21881594 | Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. | Genes Immun | 2012 |
| 21356110 | Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. | BMC Pulm Med | 2011 |
| 21803750 | Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. | Ann Rheum Dis | 2011 |
| 21798883 | Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. | Ann Rheum Dis | 2011 |
| 21613310 | Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. | Ann Rheum Dis | 2011 |
| 21294106 | American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. | Arthritis Rheum | 2011 |
| 21292833 | American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. | Ann Rheum Dis | 2011 |
| 20392292 | Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus. | Arthritis Res Ther | 2010 |
| 20618506 | Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. | Int J Dermatol | 2010 |
| 20159310 | A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. | J Am Acad Dermatol | 2010 |
| 19471949 | Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. | Arch Dermatol Res | 2009 |
| 20948567 | Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus. | Hum Genomics Proteomics | 2009 |
| 19623014 | Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease. | Transplantation | 2009 |
| 19446146 | Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. | Clin Ther | 2009 |
| 19479852 | Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. | Arthritis Rheum | 2009 |
| 17974598 | High-dose cyclophosphamide without stem cell rescue in scleroderma. | Ann Rheum Dis | 2008 |
| 18791055 | Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. | Ann Rheum Dis | 2008 |
| 18821648 | Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. | Arthritis Rheum | 2008 |
| 18512816 | A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. | Arthritis Rheum | 2008 |
| 18648529 | Type I interferon: potential therapeutic target for psoriasis? | PLoS One | 2008 |
| 17469162 | Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. | Arthritis Rheum | 2007 |
| 18089254 | Assessing body image in patients with systemic sclerosis (scleroderma): validation of the adapted Satisfaction with Appearance Scale. | Body Image | 2007 |
| 17717203 | Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. | Am J Respir Crit Care Med | 2007 |
| 16150792 | Long term safety of etanercept in elderly subjects with rheumatic diseases. | Ann Rheum Dis | 2006 |
| 17105853 | Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept. | Ann Rheum Dis | 2006 |
| 17133609 | Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. | Arthritis Rheum | 2006 |
| 16732547 | Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. | Arthritis Rheum | 2006 |
| 16790698 | Cyclophosphamide versus placebo in scleroderma lung disease. | N Engl J Med | 2006 |
| 16465657 | Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. | J Rheumatol | 2006 |
| 16465653 | Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. | J Rheumatol | 2006 |
| 16395747 | Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. | J Rheumatol | 2006 |
| 16541481 | Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. | J Rheumatol | 2006 |
| 16540546 | Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. | Ann Rheum Dis | 2006 |
| 16536638 | Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. | Drugs Aging | 2006 |
| 15962833 | Tumor necrosis factor inhibitors: following best practice. | Manag Care | 2005 |
| 14978663 | High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. | Semin Arthritis Rheum | 2004 |
| 15593189 | Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. | Arthritis Rheum | 2004 |
| 15279719 | Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature. | Neuro Oncol | 2004 |
| 12805086 | Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. | Am J Respir Cell Mol Biol | 2003 |
| 12905481 | Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. | Arthritis Rheum | 2003 |
| 14563355 | Cytokine regulation of pulmonary fibrosis in scleroderma. | Cytokine Growth Factor Rev | 2003 |
| 14677184 | Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. | J Rheumatol | 2003 |
| 14665486 | Age and risk of pulmonary arterial hypertension in scleroderma. | Chest | 2003 |
| 14569209 | The role of chemokines in the pathogenesis of scleroderma. | Curr Opin Rheumatol | 2003 |